[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].
Lists
Only you see this
Abstract
Nilotinib is a more effective and safe treatment option for imatinib-resistant or -intolerant CML-CP patients.
BibTeX
@inproceedings{wang2010nilotinib,
author = {Aihua Wang and Li Zhou and Jianhua You and Li Wang and Junmin Li and Jiong Hu and Zhixiang Shen},
title = {{[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].}},
booktitle = {PubMed},
year = {2010},
}Loading related content...